Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial

In the randomized, phase II (part 1) ATTRACTION-4 trial, nivolumab combined with chemotherapy [S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (CapeOX)] was evaluated in patients with chemonaïve, unresectable advanced or recurrent gastric/gastroesophageal junction cancer. Nivolumab plus SOX/CapeOX was well tolerated and demonstrated encouraging efficacy in this population.